Shopping Cart
- Remove All
- Your shopping cart is currently empty
Imatinib-d8 (STI571 D8) is a 2H-labeled version of Imatinib. Imatinib is a multi-target receptor tyrosine kinase inhibitor with anti-tumor activity, selectively inhibiting BCR-ABL, v-Abl, PDGFR, c-kit kinases, and is used in chronic myeloid leukemia treatment.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $408 | 7-10 days | |
5 mg | $1,139 | 7-10 days | |
10 mg | $1,869 | 7-10 days |
Description | Imatinib-d8 (STI571 D8) is a 2H-labeled version of Imatinib. Imatinib is a multi-target receptor tyrosine kinase inhibitor with anti-tumor activity, selectively inhibiting BCR-ABL, v-Abl, PDGFR, c-kit kinases, and is used in chronic myeloid leukemia treatment. |
Alias | STI571 D8, STI 571 D8, Imatinib D8, CGP-57148B D8, CGP57148B D8 |
Molecular Weight | 501.65 |
Formula | C29H23D8N7O |
Cas No. | 1092942-82-9 |
Smiles | N(C=1N=C(C=CN1)C=2C=CC=NC2)C3=CC(NC(=O)C4=CC=C(CN5C(C(N(C)C(C5([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])C=C4)=CC=C3C |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | DMSO: 8 mg/mL (15.95 mM), Sonication is recommended. H2O: 5 mg/mL (9.97 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
H2O/DMSO
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.